Joint Workshop to Address Lack of Drug-Radiotherapy Combinations

The field of medical oncology is undergoing a remarkable transformation. Cancers that were once considered death sentences, such as multiple myeloma and metastatic melanoma, are turning into chronic diseases due to the use of novel, targeted systemic therapies. Immunotherapy is altering the natural history of certain malignancies.

Read More

AACR Team Science Awardees Devise a Method to Detect Common Cancers Early

Early detection of cancer is arguably a holy grail in the field of cancer research. Catching the disease at an early stage could ultimately prevent thousands of deaths from late-diagnosed disease, which is more challenging to treat. Early detection tests exist for a handful of individual cancers, but no approved method can simultaneously screen for multiple types of cancer.

Read More

FDA Approves Targeted Radiotherapy for Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) recently added a new therapeutic to the armamentarium for oncologists treating patients with neuroendocrine tumors. The new therapeutic—lutetium (Lu) 177 dotatate (Lutathera)—is a targeted form of systemic radiotherapy.

Read More

Women in Science: AACR Leaders Share Their Stories

In honor of International Day of Women and Girls in Science, a United Nations initiative aimed at narrowing a global gender gap in the scientific work force, several AACR leaders shared how they initially became interested in science, how they built rewarding careers in cancer research, and how they might advise a girl or young woman considering a career in science.

Read More

FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer

On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain patients with metastatic, HER2-negative breast cancer. The FDA also granted marketing authorization for a test to identify those patients eligible to receive olaparib: patients with an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

Biosimilars: Breaking Through to Cancer Treatment

A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical therapies has recently borne fruit for the cancer community in the form of two new therapeutic options for a wide range of cancers—bevacizumab-awwb (Mvasi) and trastuzumab-dkst (Ogivri).

Read More

Holding Tobacco Companies Accountable for Deceptive Ads

The relationship between cigarette smoking and lung cancer was first brought to the public’s attention more than 50 years ago, when the U.S. Surgeon General’s report on “Smoking and Health” was published. However, tobacco companies are only now telling the truth about their deadly products, and only thanks to a 2006 court order that they spent more than a decade trying to overturn.

Read More